OncoCyte Corporation
OCX
$3.44
$0.051.48%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 25.15% | -51.54% | -7.08% | 57.94% | 56.89% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 25.15% | -51.54% | -7.08% | 57.94% | 56.89% |
| Cost of Revenue | 19.36% | -15.50% | -16.96% | -4.90% | 13.86% |
| Gross Profit | 36.73% | -104.56% | 128.00% | 338.18% | 542.31% |
| SG&A Expenses | 4.52% | -18.96% | -31.88% | -34.36% | -37.14% |
| Depreciation & Amortization | 0.00% | -1.12% | -1.12% | -2.22% | -8.33% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.71% | -4.41% | -14.44% | -17.85% | -20.20% |
| Operating Income | -4.40% | 1.44% | 14.76% | 20.28% | 22.76% |
| Income Before Tax | -144.07% | -106.63% | -122.96% | -332.28% | -33.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -144.07% | -106.63% | -122.96% | -332.28% | -33.54% |
| Earnings from Discontinued Operations | -- | 100.00% | 100.00% | 100.00% | 94.61% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -118.36% | 24.00% | 39.37% | 32.96% | 61.89% |
| EBIT | -4.40% | 1.44% | 14.76% | 20.28% | 22.76% |
| EBITDA | -5.32% | -4.72% | 7.26% | 11.43% | 12.80% |
| EPS Basic | -25.42% | 51.66% | 57.34% | 52.18% | 72.92% |
| Normalized Basic EPS | 36.37% | 37.52% | 43.40% | 44.60% | 44.35% |
| EPS Diluted | -25.42% | 51.66% | 57.34% | 52.18% | 73.05% |
| Normalized Diluted EPS | 36.35% | 37.50% | 43.38% | 44.59% | 44.37% |
| Average Basic Shares Outstanding | 70.85% | 52.67% | 45.31% | 40.03% | 38.13% |
| Average Diluted Shares Outstanding | 70.83% | 52.64% | 45.28% | 40.01% | 38.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |